<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28542556</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.</ArticleTitle><Pagination><StartPage>e0178259</StartPage><MedlinePgn>e0178259</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0178259</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0178259</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a major causative agent of hand-foot-and-mouth disease (HFMD) frequently occurring in children. HFMD induced by EV71 can cause serious health problems and has been reported worldwide, particularly in the Asia-Pacific region. In this study, we assessed the immunogenicity of a formalin-inactivated HFMD vaccine using an EV71 strain (FI-EV71 C4a) isolated from a Korean patient. The vaccine candidate was evaluated in mice to determine the vaccination doses and vaccine schedules. BALB/c mice were intramuscularly administered 5, 10, or 20 &#x3bc;g FI-EV71 vaccine, followed by a booster 2 weeks later. EV71-specific antibodies and neutralizing antibodies were induced and maintained until the end of the experimental period in all vaccinated groups. To determine the effectiveness of adjuvant for the EV71 vaccine, three adjuvants, i.e., aluminium hydroxide gel, monophosphoryl lipid A, and polyinosinic-polycytidylic acid, were administered separately with the FI-EV71 vaccine to mice via the intramuscular route. Mice administered the FI-EV71 vaccine formulated with all three adjuvants induced a significantly increased antibody response compared with that of the single adjuvant groups. The vaccinated group with triple adjuvants exhibited more rapid induction of EV71-specific and neutralizing antibodies than the other groups. These results suggested that the role of adjuvant in inactivated vaccine was important for eliciting effective immune responses against EV71. In conclusion, our results showed that FI-EV71 was a potential candidate vaccine for prevention of EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>In</LastName><ForeName>Hyun Ju</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Heeji</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung-Ah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin-Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyeon</LastName><ForeName>Ji-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Sang-Gu</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>June-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jung Sik</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Young Ki</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0003-0027-0134</Identifier><AffiliationInfo><Affiliation>Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28542556</ArticleId><ArticleId IdType="pmc">PMC5443535</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0178259</ArticleId><ArticleId IdType="pii">PONE-D-17-04901</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong SS, Yip CC, Lau SK, Yuen KY. Human enterovirus 71 and hand, foot and mouth disease. Epidemiology and infection. 2010;138(8):1071&#x2013;89. Epub 2010/01/09. doi: 10.1017/S0950268809991555
</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268809991555</ArticleId><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al.
Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerging infectious diseases. 2003;9(4):461&#x2013;8. Epub 2003/04/19. PubMed Central PMCID: PMCPMC2957976. doi: 10.3201/eid0904.020395
</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, Cardosa MJ. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol. 2001;75(16):7732&#x2013;8. Epub 2001/07/20. PubMed Central PMCID: PMCPMC115010. doi: 10.1128/JVI.75.16.7732-7738.2001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7732-7738.2001</ArticleId><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999;73(12):9969&#x2013;75. Epub 1999/11/13. PubMed Central PMCID: PMCPMC113047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-S, Tseng F-C, Wang J-R, Chi C-Y, Chong P, Su I-J. Challenges to Licensure of Enterovirus 71 Vaccines. PLoS Negl Trop Dis. 2012;6(8):e1737
doi: 10.1371/journal.pntd.0001737
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001737</ArticleId><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious diseases. 2010;10(11):778&#x2013;90. Epub 2010/10/22. doi: 10.1016/S1473-3099(10)70194-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Human vaccines &amp; immunotherapeutics. 2013;9(8):1701&#x2013;5. Epub 2013/06/08. PubMed Central PMCID: PMCPMC3906269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsbroek E, Ruitenberg EJ. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine. 2010;28(22):3778&#x2013;83. Epub 2010/04/07. doi: 10.1016/j.vaccine.2010.02.095
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.02.095</ArticleId><ArticleId IdType="pubmed">20362626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Li N, Yu X, Yao X, Li F, Lu F, et al.
Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Archives of Virology. 2012;157(1):37&#x2013;41. doi: 10.1007/s00705-011-1136-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1136-3</ArticleId><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, et al. Production of EV71 vaccine candidates. Human vaccines &amp; immunotherapeutics. 2012;8(12):1775&#x2013;83. Epub 2012/09/21. Central PMCID: PMCPMC3656065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, et al.
Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30(22):3295&#x2013;303. Epub 2012/03/20. doi: 10.1016/j.vaccine.2012.03.010
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al.
Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8(11):e79783 Epub 2013/11/28. PubMed Central PMCID: PMCPMC3836818. doi: 10.1371/journal.pone.0079783
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Wang J. EV71 vaccine, an invaluable gift for children. Clinical &amp; Translational Immunology. 2014;3(10):e28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, et al.
EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28(20):3516&#x2013;21. Epub 2010/03/23. doi: 10.1016/j.vaccine.2010.03.003
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-S, Chang L-Y. Development of enterovirus 71 vaccines. Expert Review of Vaccines. 2010;9(2):149&#x2013;56. doi: 10.1586/erv.09.152
</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao F, Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Frontiers of Medicine. 2012;7(1):111&#x2013;21. doi: 10.1007/s11684-012-0237-z
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-012-0237-z</ArticleId><ArticleId IdType="pubmed">23247645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2013;381(9882):2024&#x2013;32. Epub 2013/06/04.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappuoli R. Twenty-first century vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences. 2011;366(1579):2756&#x2013;8. doi: 10.1098/rstb.2011.0075
</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2011.0075</ArticleId><ArticleId IdType="pmc">PMC3146774</ArticleId><ArticleId IdType="pubmed">21893537</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nature reviews Immunology. 2009;9(4):287&#x2013;93. PubMed Central PMCID: PMC3147301. doi: 10.1038/nri2510
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2510</ArticleId><ArticleId IdType="pmc">PMC3147301</ArticleId><ArticleId IdType="pubmed">19247370</ArticleId></ArticleIdList></Reference><Reference><Citation>Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine. 2008;26(24):3036&#x2013;45. doi: 10.1016/j.vaccine.2007.12.002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.12.002</ArticleId><ArticleId IdType="pubmed">18226433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628&#x2013;32. doi: 10.1126/science.1138963
</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1138963</ArticleId><ArticleId IdType="pubmed">17569868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortier ME, Kent S, Ashdown H, Poole S, Boksa P, Luheshi GN. The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. American journal of physiology Regulatory, integrative and comparative physiology. 2004;287(4):R759&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, et al.
Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8(2):e57601 Epub 2013/03/02. PubMed Central PMCID: PMCPMC3579802. doi: 10.1371/journal.pone.0057601
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH. Enterovirus 71 infection: An experience in Korea, 2009. Korean J Pediatr. 2010;53(5):616&#x2013;22. doi: 10.3345/kjp.2010.53.5.616
</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2010.53.5.616</ArticleId><ArticleId IdType="pmc">PMC2994121</ArticleId><ArticleId IdType="pubmed">21189926</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi-Sun R, Byunghak K, Jiyoung H, Seoyeon H, Ahyoun K, Jonghyun K. Enterovirus 71 Infection with Central Nervous System Involvement, South Korea. Emerging Infectious Disease journal. 2010;16(11):1764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3294506</ArticleId><ArticleId IdType="pubmed">21029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel FR. Improving Vaccine Performance with Adjuvants. Clinical Infectious Diseases. 2000;30(Supplement 3):S266&#x2013;S70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10875797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CCY, Lau SKP, Woo PCY, Yuen K-Y. Human enterovirus 71 epidemics: what's next? Emerging Health Threats Journal. 2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Current opinion in immunology. 2010;22(3):411&#x2013;6. doi: 10.1016/j.coi.2010.04.004
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2010.04.004</ArticleId><ArticleId IdType="pubmed">20466528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecologic oncology. 2008;110(3 Suppl 1):S1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18653222</ArticleId></ArticleIdList></Reference><Reference><Citation>Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. Journal of immunology (Baltimore, Md: 1950). 2014;193(4):1920&#x2013;30. Epub 2014/07/16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25024381</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert review of vaccines. 2011;10(4):471&#x2013;86. Epub 2011/04/22. doi: 10.1586/erv.11.29
</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.29</ArticleId><ArticleId IdType="pubmed">21506645</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumke HC, Richardus JH, Rombo L, Pauksens K, Plassmann G, Durand C, et al.
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC infectious diseases. 2013;13:348 PubMed Central PMCID: PMC3729430. doi: 10.1186/1471-2334-13-348
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-348</ArticleId><ArticleId IdType="pmc">PMC3729430</ArticleId><ArticleId IdType="pubmed">23890405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, et al.
Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine. 2014;32(43):5730&#x2013;9. doi: 10.1016/j.vaccine.2014.08.029
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.029</ArticleId><ArticleId IdType="pubmed">25173481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32(14):1595&#x2013;601. doi: 10.1016/j.vaccine.2013.10.081
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.10.081</ArticleId><ArticleId IdType="pubmed">24606637</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DGW, Trasti SL, Tan EL, Alonso S. Sustained High Levels of Interleukin-6 Contribute to the Pathogenesis of Enterovirus 71 in a Neonate Mouse Model. Journal of Virology. 2011;85(7):3067&#x2013;76. doi: 10.1128/JVI.01779-10
</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01779-10</ArticleId><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T-Y, Hsia S-H, Huang Y-C, Wu C-T, Chang L-Y. Proinflammatory Cytokine Reactions in Enterovirus 71 Infections of the Central Nervous System. Clinical Infectious Diseases. 2003;36(3):269&#x2013;74. doi: 10.1086/345905
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345905</ArticleId><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-M, Lei H-Y, Huang K-J, Wu J-M, Wang J-R, Yu C-K, et al.
Pathogenesis of Enterovirus 71 Brainstem Encephalitis in Pediatric Patients: Roles of Cytokines and Cellular Immune Activation in Patients with Pulmonary Edema. Journal of Infectious Diseases. 2003;188(4):564&#x2013;70. doi: 10.1086/376998
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, et al.
Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. European journal of immunology. 1995;25(3):823&#x2013;9. Epub 1995/03/01. doi: 10.1002/eji.1830250329
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830250329</ArticleId><ArticleId IdType="pubmed">7705414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease. Journal of Virology. 2010;84(1):661&#x2013;5. doi: 10.1128/JVI.00999-09
</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>